Although the hallmark of long-QT syndrome (LQTS) is abnormal cardiac repolarization, there are varying degrees of phenotypic expression and arrhythmic risk. Our aim was to evaluate the performance of a morphological T-wave analysis program in defining breakthrough LQTS arrhythmic risk beyond the QTc value.
L
ong-QT syndrome (LQTS) is a leading cause of sudden cardiac death in the young. 1 Patients with LQTS have abnormal or delayed ventricular repolarization that often manifests itself as a prolonged QT interval on the surface ECG. This abnormality of repolarization predisposes to life-threatening cardiac events (CEs). Although it is established that life-threatening arrhythmias often occur under specific circumstances in a gene-specific manner, 2 the ability to identify those at highest phenotypic risk of CEs remains poor, particularly in those at risk of continued arrhythmic events while being treated intentionally for their underlying LQTS substrate. 3 Improved phenotypic characterization of patients with LQTS who are at higher risk of ongoing CEs is crucial and has the potential to serve 2 purposes. First, it would enable those at higher risk to receive appropriate care and intervention. Second, and equally as important, it would enable identifying those at lower risk, thereby avoiding overaggressive treatment, 4 including potentially unnecessary implantation of an implantable cardioverter defibrillator (ICD) which has many recognized complications, including anxiety, 5 infection, 6 and inappropriate shock. 7 Although significant inroads have been made in identifying potential modifier genes to account for phenotypic differences, detailed analysis of repolarization itself has largely not been performed even though the surface ECG is inexpensive, easily obtained, and remains central to the diagnosis of LQTS. Use of markers of ventricular repolarization on the surface ECG to predict arrhythmic events (apart from the QTc) has been limited. 8, 9 Previously, we have quantified informative T-wave morphological changes that identified those at highest risk of torsade de pointes with class III antiarrhythmic loading 10 and even those patients with electrocardiographically concealed LQTS. 11 We subsequently hypothesized that architectural T-wave analysis from the surface ECG could help further risk stratify patients
WHAT IS KNOWN?
• A significant number of patients with long-QT syndrome have break through cardiac events despite optimal therapy. • Current risk stratification approaches are largely focused on clinical and genetic factors even though the primary abnormality in long-QT syndrome is repolarization. Beyond the QT interval, there has been limited application and examination of the surface ECG for repolarization abnormalities.
WHAT THE STUDY ADDS?
• Architectural T-wave morphological analysis from the surface ECG can detect subtle changes in the T wave and cardiac repolarization.
• We have identified a novel set of surface ECG markers (T-wave morphological features) with the power to predict breakthrough arrhythmic events. Specifically, left slope of T wave in lead V6 and T-wave center of gravity x axis (last 25% of wave) in lead I were the best predictors. • This has the potential to help develop an individualized targeted therapeutic approach and further refine clinical decision making in patients with long-QT syndrome.
with LQTS, independent of the QTc. Accordingly, our aim is to identify and evaluate the ability of morphological T-wave analysis in the prediction of breakthrough arrhythmic risk and to compare this to the well-established QTc.
METHODS

Study Population
Institutional review board approval was obtained for this study. A total of 661 patients with LQTS, who were evaluated and treated at Mayo Clinic between 1999 and 2015, formed our initial cohort. In this cohort, genetic testing was positive in 596 patients (90%), of whom 287 (43%) were LQT1 (KCNQ1), 204 (31%) were LQT2 (KCNH2), 56 (9%) were LQT3 (SCN5A), 20 (3%) were LQT4-17 (minor genes), and 29 (4%) had multiple LQTS-associated mutations. Subsequently, we excluded LQT3-17 and multiple mutations because of their smaller sample sizes. Our final cohort therefore contained only patients with either LQT1 or LQT2 (n=491). We excluded those patients who had an unreadable ECG either because of unreadable T waves (biphasic T wave [that is a T wave that crosses the isoelectric line with a positive and a negative deflection], small amplitude <0.1 mV), ventricular paced rhythm, presence of a bundle branch block, or atrial fibrillation (n=84; 5 of these patients had a breakthrough cardiac event [BCE] ). The primary outcome evaluated was the occurrence of an LQTS-related BCE, which was defined as arrhythmogenic syncope, seizure, aborted cardiac arrest, appropriate ICD shock, or sudden cardiac death after their first evaluation at our specialty center. Events were abstracted from the electronic medical record by 2 authors (A.S. and R.R.) with Dr Ackerman providing final adjudication when there was disagreement. Comparison between groups was done using Pearson χ 2 for categorical variables or Wilcoxon rank-sum test for continuous variables. Incidence of LQTS-associated BCEs was estimated using Kaplan-Meier methods, and groups were compared using the log-rank test.
T-Wave Analysis
We analyzed the first ECG recorded at our institution with the initial consultation (Mayo Clinic, Rochester MN). The 12-lead surface ECG was analyzed using our novel, proprietary T-wave analysis program as previously described. 10 Part A in the Data Supplement provides further detailed information on the analysis, but briefly, the raw, 12-lead ECG tracings were uploaded into our automated software tool. Preprocessing procedures were applied to enable denoising and baseline correction. This was followed by ECG feature extraction using our automated software program. ECG features (mentioned below) from the ECG are detected by a Bayesian statistical peak delineation algorithm. 12 The software analyzes multiple beats over a 10-second ECG strip. The operator of the software was unaware of the arrhythmic event status of the subject when analyzing the 12-lead surface ECG. The repolarization features collected for analysis are illustrated in Figure 1 
Missing Values
Leads were excluded from analysis if the T wave was of low amplitude (<0.1 mV) or if there was biphasic T-wave inversion because of the limits this creates on ECG and in particular T-wave analysis. If a lead or a variable was missing >20% of values, this was excluded from the final analysis. For the remaining leads (I, II, V4, V5, V6, aVR), missing values were imputed using the Markov Chain Monte Carlo method.
ECG Feature Selection/Statistical Analysis
Baseline variables are presented as number and percentage or with median and quartiles, as appropriate. Because of the nature of the distribution of some ECG parameters to minimize potential effects of outliers and increase power, all ECG parameters were categorized into quartiles (1, 2, 3, 4) and then analyzed as an ordinal trend across these quartiles. Time to event analyses were used to examine the occurrence of first LQTS-related BCE after this analyzed ECG and subjects without any such events were censored at last available clinical follow-up. Incidence of LQTS-associated BCEs was estimated using Kaplan-Meier methods. As mentioned above leads I, II, V4, V5, V6, and aVR were used for this analysis. Because of the number of ECG parameters in relation to the number of subjects and events, we chose to use a leave one out cross-validation for model selection to minimized overfitting. Essentially, this method uses a score selection method within Cox proportional hazards regression and counts the number of times each parameter is entered into the model across all 407 leave one out cross-validation sets. The final model is chosen based on the number of times each variable is chosen. 13 After the final set of ECG parameters was chosen, the model was fit on the entire set of data, and results were summarized with hazard ratio (HR) and associated 95% confidence limits. Association of QTc and β-blocker use with LQTS-associated BCEs was then evaluated in models with chosen ECG parameters. As a measure of ability of the model to discriminate those with and without BCEs, survival C statistics were also estimated and validated using a leave one out cross-validation approach. Subgroup analyses were also conducted within each genotype group, but because of sample size, the model selection was not repeated within these subgroups. Analyses were done using SAS version 9.4, and 2-sided P<0.05 was considered to be statistically significant.
RESULTS
The final study cohort was composed of 246 patients (43% men) with LQT1 and 161 patients (41% men) with LQT2. Clinical characteristics of the total population are shown in Table 1 . Table 2 describes the baseline characteristics per LQTS genotype. Over the mean follow-up period of 6.4±3.9 years, 23 patients experienced ≥1 defined BCEs with 5-and 10-year event rates of 4% and 7% (Table 3) . Please see Part B in the Data Supplement for individual details of the BCEs experienced by these 23 patients while presumably compliant with their intentional LQT1-or LQT2-directed treatment program.
T-Wave Features
Analysis of the total LQT1 and LQT2 cohort with multivariable Cox proportional hazards regression identified 2 independent predictors of future LQTS-associated BCEs from the surface ECG: left slope of T wave in lead V6 and T-wave center of gravity (COG) x axis (last 25% of wave) in lead I (Table 4) . These results remained consistent after being adjusted for the patient's individual QTc value and a history of prior CEs (Part C in the Data Supplement; Tables 1-3 Figure 2 shows the Kaplan-Meier eventfree survival for the selected T-wave features and QTc stratified by quartiles (Figure 2A , T-wave COG x axis [last 25% of wave]; Figure 2B , T-wave left slope; and Figure 2C , QTc). Graphs with confidence intervals are provided in the Part D in the Data Supplement (Figures 1-3) .
The discriminative powers of the selected features were also evaluated using cross-validation C statistics. Importantly, the ECG features show additive value to the QTc. The combination of the left slope of T wave in lead V6 and T-wave COG x axis (last 25% of wave) in lead I resulted in a C statistic of 0.77 (0.65-0.89). This was better than the QTc alone 0.68 (0.58-0.77). In a model with all 3 features, the C statistic slightly improved to 0.78 (0.67-0.90). Q1  97  66  25  88  48  18  89  72  31  Q2  90  52  22  87  55  18  90  45  13  Q3  86  46  18  88  53  24  90  48  22  Q4  82  39  12  92  47  17  86  38 
Genotype-Specific Analysis
When examined specifically by genotype (Table 5 In contrast, for patients with LQT2 ( 14) were not significantly associated with risk of LQT2-associated BCEs. The cross-validated C statistic with all 3 features was strong at 0.82 (0.71-0.93).
β-Blocker Therapy
In a secondary analysis controlling for β-blocker therapy (which was recorded at time of ECG analysis), similar risks were observed. There was good discrimination in the overall cohort, with limited discrimination in LQT1 and strong discrimination in LQT2 (Part E in the Data Supplement).
DISCUSSION
This study extends on our previous work, which demonstrated that comprehensive T-wave morphological and morphometric analysis (aka, the T-wave fingerprint) could discriminate patients with concealed LQTS from healthy controls. 11 The main finding of this current study was the identification of a potential novel set of Model (1) is independent ECG features, and model (2) is addition of QTc to the model. CI indicates confidence interval; COG, center of gravity; and LQT1, long-QT syndrome 1. Q1  57  43  16  25  16  9  5 5  4 5  2 1  Q2  51  28  11  51  30  11  52  26  4  Q3  52  28  12  58  36  14  55  27  15  Q4  54 surface ECG markers with the power to predict breakthrough arrhythmic events particularly in patients being treated for the second most common LQTS genotype, namely LQT2. Specifically, the T-wave left slope in lead V6 and the T-wave COG x axis (last 25% of wave) in lead I were able to identify those patients with LQT2 at higher risk of future events. These findings potentially create an enhanced path toward personalized clinical approaches for patients with LQTS.
Personalized approaches and identification of patients with LQTS at increased risk of CEs are imperative as the current mainstay treatment options: β-blocker therapy, left cardiac sympathetic denervation, and an ICD, all have the potential of unwanted complications. Nearly one half of the patients who pursue left cardiac sympathetic denervation at our institution do so because of unacceptable quality of life on β-blocker therapy (self-described β-blocker zombies). However, with left cardiac sympathetic denervation, a warmer and drier left hand is expectant, and a droopy left eyelid can occur.
14 ICDs are associated with adverse events, including infection, malfunction, inappropriate shocks, and anxiety in ≈25% of patients with LQTS. 4, 7 We think our data may facilitate an individualized approach to identify those at highest risks who may benefit most from various treatment options.
To date, risk stratification of LQTS has focused largely on clinical and genetic factors at predicting the likelihood of CEs. There has been limited examination of the repolarization (beyond the QT interval itself) specifically in LQTS. 9, 15 Historically, the corrected QT interval (QTc) has been and still is the major ECG marker used to help identify those at greatest risk of CEs. 16 The major issue with the lone use of the QTc is that 25% to 50% of patients with LQTS may have a QTc in the normal or borderline range and subsequently express a concealed phenotype. Even though these patients have a much lower risk of events, they still exhibited a >10-fold increase in the risk compared Q1  40  23  9  6 3  3 2  9  34  27  10  Q2  39  24  11  36  25  7  3 8  1 9  9  Q3  34  18  6  3 0  1 7  1 0  3 5  2 1  7  Q4  28  15  3  1 2  6  3  3 4  1 with genetically and phenotypically unaffected family members. 17 Unfortunately, the small sample size in the concealed phenotype group does not give us sufficient power to determine the discriminative power of T-wave analysis in this group. However, because T-wave abnormalities were not correlated to QTc duration (data not shown), these T-wave features, in addition to the QTc, represent 2 independent prognostic indexes. Clinically, this could be useful in the identification of a higher risk patient with LQTS who nevertheless has reassuring QTc values.
Notably, the T-wave features that were determined in this study to be predictors of events are similar to those that were able to distinguish patients with concealed LQTS from healthy controls in our prior work. 11 We hypothesize that these selected features emerged because they are markers (endophenotypes) reflecting the different expressivity of potassium channel inhibition (I Kr and I Ks ). In terms of the COG x axis last 25% of the T wave, we propose 2 potential reasons for its emergence as an LQT2-associated endophenotype. First, macroscopic notching in their T wave, in particular LQT2, will cause prolongation of the COG whether mild or marked, and this likely results in a shift along the x axis. The greater the shift the greater the risk of events. Interestingly, notched T-wave patterns have been described more frequently in those with a pore mutation in the LQT2-associated Kv11.1 channels than those with a nonpore mutation, with pore mutations more likely to have significant CEs. 18 In addition, it is been known that I Kr has a greater effect of the M cells in the midmyocardium which impacts on the determination of the end of the T wave. 19, 20 Regarding the inverse relationship between left slope of the T wave in V6 and arrhythmic risk, we hypothesize that this feature emerged because of the role of I Ks and I Kr in the formation of ascending limb of the T wave and T-wave amplitude. 20 Interestingly, the Tpeak to Tend interval did not emerge as a significant marker of breakthrough events in our cohort even though this interval is considered a reasonable marker of arrhythmogenic risk. 21, 22 It is unclear why the Tpeak to Tend interval underperformed as prolongation of this interval correlates with increased risk of mortality and ventricular arrhythmias in acquired LQTS, 23 hypertrophic cardiomyopathy, 24 patients receiving primary percutaneous coronary intervention for a myocardial infarction, 25 and Brugada syndrome. 21 Neverthless, our results support previous work by others that have shown an inability of the Tpeak to Tend interval in on either the surface ECG 26 or Holter monitor 27, 28 to predict symptoms or syncope.
Clinical Application
Our data have highlighted new ECG markers that predict breakthrough arrhythmic risk in LQTS, particularly in LQT2. This observation could have broad clinical application because the ECG is inexpensive and universally performed in patients with LQTS. Ultimately, this approach could improve risk stratification and facilitate personalized care that targets intensification of the LQT2-directed treatment program to those at highest risk. This approach could allow physicians and patients to make more informed decisions and provide a window into the likelihood of future events among those who are currently asymptomatic.
Limitations
Although this is a large study population and provides interestingly novel insights, there are some noteworthy limitations. First, although we performed cross-validation within this study, we did not test our results on a separate validation cohort and thus cannot comment on generalizability of these findings. Second, although beneficial for our patients, given the sparse number of patients with BCEs (N=23; 5%), cross-validation can only minimize and not eliminate potential overfitting, Furthermore, we were limited to the number of predictors we could build into our model, and therefore genotype analysis should be taken within the context of our study limitations. We did not take into account other modifiable risks after the first ECG, such as left cardiac sympathetic denervation or ICD implantation. Last, it is possible that the coexistence of known and yet to be determined modifier genes affected the outcomes of patients, and we did not systematically examine for this.
Conclusion
Architectural T-wave analysis and the generation of a T-wave fingerprint from the surface ECG have the ability to enhance risk stratification for patients with LQTS, especially LQT2. In particular, a decreasing T-wave left slope and an increasing T-wave COG x axis (last 25% of the wave) can help identify those who remain at increased risk of a LQT2-triggered BCE. This has the potential to help define an individualized targeted therapeutic approach and further refine clinical decision making. 
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